Teva Pharmaceutical Industries Ltd (TEVA) stock is lower by 9.45% over the past week and gets a Neutral rating from InvestorsObserver Sentiment Indicator.
Teva Pharmaceutical Industries Ltd has a Neutral sentiment reading. Find out what this means for you and get the rest of the rankings on TEVA!
In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company.
Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish.
InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion.
For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.
What's Happening With TEVA Stock Today?
Teva Pharmaceutical Industries Ltd (TEVA) stock is trading at $8.62 as of 9:42 AM on Thursday, Jun 9, a loss of -$0.19, or -2.16% from the previous closing price of $8.81. The stock has traded between $8.62 and $8.77 so far today. Volume today is low. So far 16,229 shares have traded compared to average volume of 9,296,253 shares.
To screen for more stocks like Teva Pharmaceutical Industries Ltd click here.
More About Teva Pharmaceutical Industries Ltd
Based in Israel, Teva is one of the world's largest generic drug manufacturers, with over 3,500 products marketed in over 60 countries. While a majority of its revenue is attributed to prescription generic drugs, Teva develops and markets its own branded specialty and biopharmaceutical products, primarily in the U.S. and in Europe. The company's branded portfolio generates one fifth of total revenue and consists of patented therapies targeting central nervous system conditions (Austedo, Ajovy, Copaxone), oncology (Bendeka/Treanda), and respiratory conditions (ProAir, Qvar). While global competition has facilitated the commodification of small-molecule generic drugs, Teva's portfolio rationalization has resulted in less overall price erosion versus peers.
Click Here to get the full Stock Report for Teva Pharmaceutical Industries Ltd stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
